Chemical Company DuPont Shines In Q2: Earnings Beat, Boosts Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 31 2024
0mins
Should l Buy DD?
Source: Benzinga
Financial Performance: DuPont reported better-than-expected second-quarter results with adjusted EPS of $0.97 and sales of $3.171 billion, driven by a 15% increase in Electronics & Industrial sales, while overall organic sales remained flat year-over-year.
Strategic Plans: The company announced plans to separate its Electronics and Water businesses into distinct entities within 18 to 24 months, aiming to enhance focus and value for shareholders, while raising its 2024 adjusted EPS outlook to $3.70 - $3.80.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DD
Wall Street analysts forecast DD stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 45.800
Low
44.00
Averages
49.30
High
59.00
Current: 45.800
Low
44.00
Averages
49.30
High
59.00
About DD
DuPont de Nemours, Inc. is engaged in providing advanced solutions that help transform industries. The Company serves various markets, including healthcare, water, construction, and industrial. It operates through two segments, which include Healthcare & Water Technologies and Diversified Industrials. The Healthcare & Water Technologies segment includes packaging, parts and components for medical device and biopharma markets as well as water filtration and purification technologies primarily for industrial wastewater & energy, municipal drinking water & desalination, and life sciences & specialty markets. The Diversified Industrials segment includes building technologies, with a portfolio serving new-build and repair/remodel applications across non-residential and residential construction markets, and industrial technologies, which includes a portfolio of adhesive, wear and friction, and packaging solutions serving aerospace, automotive and printing and packaging markets.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Acquisition Scale: Arclin has completed the acquisition of DuPont's Aramids business for approximately $1.8 billion, which includes the renowned Kevlar® and Nomex® brands, marking a significant expansion of Arclin's scale and capabilities in life-critical industries.
- Global Team Expansion: The acquisition adds around 1,800 new team members globally and establishes established manufacturing operations in Europe and Asia, ensuring operational continuity from day one while investing in manufacturing capabilities and innovation to support long-term growth.
- Enhanced Product Portfolio: With the integration of the Aramids brands, Arclin's portfolio now spans aerospace, electrical infrastructure, electric vehicles, and personal protection, further solidifying its leadership position in construction, infrastructure, and protective materials markets.
- Commitment to Innovation: CEO Bradley Bolduc emphasized the company's commitment to investing in technological innovation and strategically deploying Kevlar® and Nomex® across the world's most performance-critical applications to meet the growing demand for advanced protective materials.
See More
- Transaction Value: DuPont has completed the divestiture of its Aramids business, including Kevlar® and Nomex®, in a deal valued at approximately $1.8 billion, which is expected to significantly enhance the company's financial position.
- Cash Proceeds: The transaction provides DuPont with pre-tax cash proceeds of about $1.2 billion, further strengthening its liquidity and providing capital for future investments.
- Equity Stake: DuPont also receives a non-controlling common equity interest in Arclin valued at $325 million, representing an approximate 16% stake, which enhances its strategic partnership with Arclin.
- Business Reclassification: Beginning in the third quarter of 2025, the results of the Aramids business were reclassified as discontinued operations, a move that will help DuPont focus on its core operations and optimize resource allocation.
See More
- Transaction Value: DuPont has completed the divestiture of its Aramids business (Kevlar® and Nomex®) for approximately $1.8 billion, reflecting the market value and attractiveness of this segment.
- Cash Proceeds: The transaction provides DuPont with about $1.2 billion in pre-tax cash proceeds, enhancing the company's liquidity and financial flexibility, which is crucial for future investments and strategic initiatives.
- Equity Stake: DuPont also secured a non-controlling common equity interest in Arclin valued at $325 million, representing an approximate 16% stake, which offers ongoing revenue potential and market engagement opportunities.
- Business Reclassification: Beginning in Q3 2025, the results of the Aramids business were reclassified as discontinued operations, a move that allows DuPont to focus on its core operations and optimize resource allocation to improve overall operational efficiency.
See More
- Water Quality Improvement: DuPont's newly commissioned multi-tech water treatment plant in Baringo, Kenya, provides the Kampi Ya Samaki community with its first reliable drinking water source, utilizing DuPont's ultrafiltration modules and reverse osmosis elements to remove fluoride and other contaminants, significantly enhancing residents' drinking safety.
- Community Benefits: The project is expected to benefit up to 20,000 residents by supplying clean water to 1,500 households, three schools, and a health facility through an expanded distribution network, directly improving public health, particularly for women and children.
- Collaborative Model: The initiative is delivered in partnership with the Baringo County Government and various agencies, ensuring alignment with public health priorities and long-term water planning, showcasing the power of coordinated investment and shared expertise in transforming long-standing public health challenges.
- Sustainable Development: DuPont Water Solutions technologies purify over 50 million gallons of water every minute across 112 countries, demonstrating their global impact and promoting sustainable community-led water treatment solutions that help more communities gain access to clean drinking water.
See More
- Water Quality Improvement: DuPont's newly commissioned water treatment plant in Baringo, Kenya, provides the Kampi Ya Samaki community with its first reliable drinking water source, utilizing DuPont's ultrafiltration modules and reverse osmosis elements to effectively remove fluoride and other contaminants, significantly enhancing residents' drinking safety.
- Community Benefits: The project is expected to benefit up to 20,000 people by supplying clean water to 1,500 households, three schools, and a health facility through an expanded distribution network, directly improving the quality of life and health standards for local residents.
- Collaborative Model: Implemented in partnership with ChildFund and other organizations, the project aligns with public health priorities and long-term water resource planning, showcasing the importance of multi-stakeholder collaboration in addressing public health challenges.
- Socioeconomic Impact: Beyond providing safe drinking water, the project is anticipated to yield better health outcomes and reduced medical costs, particularly enhancing school attendance for women and girls, thereby promoting sustainable community development.
See More
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More











